Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 7/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | ESR1 | P03372 | 2/20 | 0.52 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 3/20 | 0.51 |
| ▸ | PPARD | Q03181 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 3/20 | 0.49 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661382 | 1.00 | CYP1A2 (0.59) | CYP1A2SLC7A5PPARGEPHX2ESR1 | |
| SCHEMBL3876493 | 1.00 | CYP1A2 (0.59) | CYP1A2SLC7A5PPARGEPHX2ESR1 | |
| SCHEMBL10436391 | 0.92 | CYP1A2 (0.68) | CYP1A2SLC7A5ESR1ESR2MME | |
| SCHEMBL10436426 | 0.86 | CYP1A2 (0.80) | CYP1A2SLC7A5ACEMMECPA1 | |
| SCHEMBL5966674 | 0.85 | ESR1 (0.54) | CYP1A2SLC7A5PPARGEPHX2ESR1 | |
| SCHEMBL11529738 | 0.85 | CYP1A2 (0.59) | CYP1A2PPARGEPHX2PPARAPPARD | |
| SCHEMBL265514 | 0.84 | CYP1A2 (0.83) | CYP1A2PPARGPPARAPPARDMME | |
| SCHEMBL491524 | 0.84 | CYP1A2 (0.83) | CYP1A2PPARGPPARAPPARDMME | |
| SCHEMBL265063 | 0.84 | CYP1A2 (0.83) | CYP1A2PPARGPPARAPPARDMME | |
| SCHEMBL12494638 | 0.84 | SLC7A5 (0.60) | CYP1A2SLC7A5MMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0692033-B1 | ENHANCEMENT OF CHEMILUMINESCENT REACTIONS | BRITISH TECH GROUP (GB) | 1998-03-11 | — | — | EP | claimed |
| EP-0210449-B1 | PROLONGED CHEMILUMINESCENCE | MILES INC. (US) | 1993-07-28 | — | — | EP | claimed |
| US-20240067599-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ABX ADVANCED BIOCHEMICAL COMPOUNDS - BIOMEDIZINISCHE FORSCHUNGSREAGENZIEN GMBH (DE) | 2024-02-29 | — | — | US | disclosed |
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| CN-114349590-A | Method for synthesizing aromatic compound | 上海巽田科技股份有限公司 | 2022-04-15 | — | — | CN | disclosed |
| WO-2021195183-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN EMBRYONIC ECTODERM DEVELOPMENT ACTIVITY AND TREATING DISEASE | EXO THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| CN-110898003-A | Novel bambuterol hydrochloride oral solution and preparation method thereof | 岳阳新华达制药有限公司 | 2020-03-24 | — | — | CN | disclosed |
| EP-1070048-B1 | CALCILYTIC COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2005-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | CYP1A2 4076/4885SLC7A5 2902/4885PPARG 746/4885 |
| US-20240067599-A1 | IODOTYROSINE DERIVATIVES AND PROCESS FOR PREPARING IODOTYROSINE DERIVATIVES | ALK, ALKBH3, INSR | CYP1A2 485/4885SLC7A5 281/4885PPARG 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.